The role of hypoxia-inducible factors in tumorigenesis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wang GL, Semenza GL . Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230–1237.
Huang LE, Gu J, Schau M, Bunn HF . Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin–proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987–7992.
Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ . Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 1997; 272: 11205–11214.
Wenger RH, Rolfs A, Marti HH, Guenet JL, Gassmann M . Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1 alpha. Biochem Biophys Res Commun 1996; 223: 54–59.
Tian H, McKnight SL, Russell DW . Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72–82.
Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y . A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273–4278.
Flamme I, Fröhlich T, von Reutern M, Kappel A, Damert A, Risau W . HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 1997; 63: 51–60.
Hu CJ, Sataur A, Wang L, Chen H, Simon MC . The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 2007; 18: 4528–4542.
Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC . Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361–9374.
Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271–273.
Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA . Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit HIF3alpha. Gene Expr 1998; 7: 205–213.
Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550–554.
Reyes H, Reisz-Porszasz S, Hankinson O . Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992; 256: 1193–1195.
Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991; 252: 954–958.
Whitelaw ML, Gustafsson JA, Poellinger L . Identification of transactivation and repression functions of the dioxin receptor and its basic helix-loop-helix/PAS partner factor Arnt: inducible versus constitutive modes of regulation. Mol Cell Biol 1994; 14: 8343–8355.
Huang LE, Arany Z, Livingston DM, Bunn HF . Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271: 32253–32259.
Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H et al. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996; 16: 1706–1713.
Maltepe E, Keith B, Arsham AM, Brorson JR, Simon MC . The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem Biophys Res Commun 2000; 273: 231–238.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–472.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464–468.
Jiang BH, Semenza GL, Bauer C, Marti HH . Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271: C1172–C1180.
Mahon PC, Hirota K, Semenza GL . FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675–2686.
Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML . Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858–861.
Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT . Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95: 11715–11720.
Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401–408.
Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005; 1: 393–399.
Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005; 1: 409–414.
Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411–421.
Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel–Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel–Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007; 38: 1310–1320.
Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2003; 23: 4721–4727.
Winter SC, Shah KA, Han C, Campo L, Turley H, Leek R et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757–766.
Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595–2604.
Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004; 10: 8554–8560.
Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 1831–1837.
Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693–4696.
Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J . Overexpression of hypoxia-inducible factor-1{alpha} in human osteosarcoma: correlation with clinicopathological parameters and su. Jpn J Clin Oncol 2007; 37: 127–134.
Mizokami K, Kakeji Y, Oda S, Maehara Y . Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol 2006; 4: 94.
Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S . Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol 2007; 13: 3176–3182.
Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004; 46: 200–208.
Irie N, Matsuo T, Nagata I . Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 2004; 21: 1–6.
Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493–501.
Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881–890.
Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH . Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 2004; 24: 9038–9047.
Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225–239.
Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49: 325–335.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 1999; 399: 271–275.
Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA . Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595–10599.
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 1993; 260: 1317–1320.
Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993; 20: 207–216.
Sprenger SH, Gijtenbeek JM, Wesseling P, Sciot R, van Calenbergh F, Lammens M et al. Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. J Neurooncol 2001; 52: 241–247.
Mazure NM, Chen EY, Laderoute KR, Giaccia AJ . Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322–3331.
Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B . Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998; 17: 5085–5094.
Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK . Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363–369.
Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391–396.
Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin Jr WG . TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147–158.
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594–601.
Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004–7014.
Hickey MM, Simon MC . Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 2006; 76: 217–257.
Dvorak HF . Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–4380.
Ryan HE, Lo J, Johnson RS . HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005–3015.
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485–490.
Chavez JC, Baranova O, Lin J, Pichiule P . The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 2006; 26: 9471–9481.
Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel–Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675–5686.
Covello KL, Simon MC, Keith B . Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005; 65: 2277–2286.
Semenza GL . HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39: 231–234.
Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11: 407–420.
Kondo K, Klco JM, Nakamura E, Lechpammer M, kaelin WG . Inhibition of HIF is necessary for tumor suppression by the von Hippel–Lindau protein. Cancer Cell 2002; 1: 237–246.
Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG . Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83.
Arabi A, Wu S, Ridderstråle K, Bierhoff H, Shiue C, Fatyol K et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 2005; 7: 303–310.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC . HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335–347.
Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD . VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002; 62: 3014–3019.
Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003; 163: 1437–1447.
Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66: 3567–3575.
Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007; 27: 157–169.
Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222–1226.
Arya M, Ahmed H, Silhi N, Williamson M, Patel HR . Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007; 28: 123–131.
Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473–22481.
Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O . Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221–1232.
Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W . Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature 2003; 425: 307–311.
Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858–864.
Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111.
Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617–628.
Yun Z, Maecker HL, Johnson RS, Giaccia AJ . Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002; 2: 331–341.
Jögi A, Øra I, Nilsson H, Poellinger L, Axelson H, Påhlman S . Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett 2003; 197: 145–150.
Helczynska K, Kronblad A, Jögi A, Nilsson E, Beckman S, Landberg G et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003; 63: 1441–1444.
Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD . Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431–5436.
Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK et al. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 2001; 220: 175–186.
Ezashi T, Das P, Roberts RM . Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102: 4783–4788.
Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663–676.
Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ . HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006; 20: 557–570.
Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8: 131–141.
Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC . Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003; 3: 75–88.
Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE . HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949–1956.
Bruick RK . Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9082–9087.
Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL . HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669–6673.
Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF . BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol Cell Biol 2007; 27: 6229–6242.
Biju MP, Akai Y, Shrimanker N, Haase VH . Protection of HIF-1-deficient primary renal tubular epithelial cells from hypoxia-induced cell death is glucose dependent. Am J Physiol Renal Physiol 2005; 289: F1217–F1226.
Moeller BJ, Cao Y, Li CY, Dewhirst MW . Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429–441.
Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8: 99–110.